PrecisionLife’s AI⁢ Revolutionizes⁢ Long COVID and ME/CFS Treatment

March 15th marked International Long COVID Awareness Day. This condition affects ⁤at least 65 million people⁤ and is increasing annually,creating a healthcare burden⁣ exceeding $1 trillion globally.

Long COVID shares commonalities with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a chronic illness characterized by fatigue that worsens with activity. Both conditions are tough to diagnose and treat due to varied symptoms and affected organs.

Despite their impact, there are no tools ⁣to accurately diagnose patients and no drugs that treat the underlying causes of the ⁤diseases. This has lead to misunderstanding ⁢and denial of the diseases, which further harms sufferers.

The UK precision ‍medicine company PrecisionLife leverages AI and combinatorial analytics to find deeper genetic associations than traditional ⁣analysis methods. This explains more about how complex diseases⁣ manifest in patients and uncovers hidden patterns in complex patient data, enabling breakthroughs in diagnostics, drug discovery, and precision medicine.

PrecisionLife⁣ co-founder and CEO Steve Gardner shared the company’s insights and ‍their success in ⁢bringing new insights to aid the diagnosis and treatment ‍of long COVID and other complex⁣ chronic diseases at the Hevolution global healthspan ⁤summit in Riyadh.

Transforming Disease Understanding Through Advanced⁤ Data Analytics

PrecisionLife’s AI-driven approach identifies combinations of⁤ genetic and non-genetic factors that drive disease in different patient subgroups,going beyond traditional genome-wide association studies (GWAS).

Gardner⁣ explains ⁣the technological⁢ foundation of the company:

Technologically, we reimagine how you analyze data, and‍ this is really the genesis of the company—bringing two sets of technology together. ⁤One that I had developed over the last 20 ⁣years ‍and another ⁤that ⁤my co-founder, a mathematician and computer scientist, ⁣had been developing for even longer—actually 30 years.

We realised that if we put those two things⁣ together, we would actually have a way of dealing with these hyper-complex, big patient datasets with all of the genomic facts, all the multi-omics, proteomics, epigenetics, and everything ⁣else like⁣ that, and correlating ‍it with things like longitudinal electronic medical records (EMR) or electronic health records (EHR) and epidemiological and environmental information.

Metrodora Institute⁤ partnership

PrecisionLife is partnering with the ⁤Metrodora‍ Institute ‍to bring researchers, doctors, and patients together ⁤to rapidly improve diagnostics, ⁤treatments, and outcomes in complex conditions like ME/CFS and long COVID.

PrecisionLife is running a series⁣ of clinical studies on 1,000 patients – 500 with ME and ⁤500 with long COVID.

“The speed and precision of our progress in these trials is remarkable,” saeid Gardner.

We identified and published the frist-ever replicated genetic associations⁤ in both ME/CFS and Long COVID.

Gardner detailed:

We have started returning results to Metrodora patients based ⁣on the specific disease risk signatures a patient has and the symptoms they are most ⁤likely to experience.

Patients come to us, and they say, this is brilliant. You know, it’s the‍ first time a test has reflected my personal view of what’s going wrong in my disease. And clinicians love it because it guides them to amending therapy.

According to Gardner, this has great possibilities for personalised medicine:

Just think about this: clinically validated novel targets and the ability ⁣to select patients who will benefit from drugs modulating that target. ⁢That’s incredible. It’s like the NHS-led RECOVERY⁢ trial in COVID-19 that discovered dexamethasone—but on steroids—because we’re using genetic evidence to pick the most promising treatments.

Further, last month, the partnership successfully reproduced key genetic risk factors for ⁤Long COVID in diverse populations, confirming 88 percent of previously identified genes.

This marks the strongest ‍genetic evidence for Long COVID and supports biomarker-driven diagnostics and ⁣targeted treatments.

Additionally, 11 out of 13 drug repurposing candidates were validated, paving the way‍ for clinical trials and personalised therapeutics.

What’s⁢ exciting about PrecisionLife’s work is its potential across a variety of spaces in medical research.

The company initially focused on biopharma,working with pharmaceutical companies and Contract Research Organizations (CROs) to uncover novel drug targets.

Such as, as ⁢gardner detailed:

When you’ve seen the same⁢ target underpinning disease in 30–40% of a major market, ⁢that ⁢might offer an opportunity to⁢ indication-switch an existing asset into a new indication.There’s real value in that.

PrecisionLife ⁣is also using genetic-based diagnostics to improve early disease identification and clinical decision-making.

Take endometriosis—it⁢ takes 8–10 years for ⁣a confirmed diagnosis via surgery. If we can turn that into a buccal swab that reports in two weeks and refers a patient accurately to a gynecologist that’s a game-changer.

Individually, these advances are crucial for patients. But when you add up the costs of delayed diagnosis and misclassification, they become very meaningful.

Additionally,precisionlife’s ⁤insights can optimise patient triage,Gardner shared:

For example,we’re working‍ with the ‍healthcare⁣ system where 5,000 patients are referred to rheumatology yearly due to a non-specific ANA test. Only 10 per cent actually have a rheumatological condition. That’s a massive misclassification problem blocking the system.

Rather than building its ‍own diagnostic business,PrecisionLife‍ is licensing its⁢ tests and decision support systems to existing healthcare infrastructures.

We don’t want to build a massive diagnostic business ourselves. The platforms we use are standard and available globally. We can license the ⁣content and clinical decision support system ⁣to operate these tests across multiple markets.and what’s exciting is that it’s almost disease-agnostic.

This model ‍allows⁢ for scalability, making their technology accessible across multiple⁣ conditions and healthcare⁤ markets worldwide.

Is the Future ‘Actively Protective’‍ Genes That Shield Against Disease?

PrecisionLife is pioneering a new approach ⁢to disease⁤ prevention by identifying ‘actively protective’ genes—genetic ⁢factors that shield certain high-risk individuals from developing diseases. Traditionally, genetic research focuses on identifying disease-causing mutations, but this new method flips the process, searching instead⁤ for individuals who should have developed a disease but remain healthy despite having high⁣ genetic risk and exposure to disease triggers.

A‍ recent study on ME/CFS identified nine protein-coding⁢ genes with protective effects,possibly counteracting known disease mechanisms related to insulin signaling,stress response,and autoimmunity.

These findings ⁣open up possibilities for new preventative therapies, including drug targets that function similarly to statins, which lower cholesterol to prevent heart disease.

Additionally, some of these protective genes⁣ could be⁣ harnessed for mRNA-based treatments, using the same technology as COVID-19 vaccines to boost natural disease resistance. This could lead to personalised protective treatments, extending healthspan and improving quality of life for high-risk individuals before ⁢disease ever develops.